Antibody Details
Product Details
ImmunogenPurified human prekallikrein.
FormulationThis monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Product PreparationPurified by Protein G affinity chromatography
Storage and HandlingThis antibody is stable for at least one (1) year at -20°C. Avoid multiple freeze-thaw cycles.
Applications and Recommended Usage?
Quality Tested by LeincoImmunoblotting: use at 1-5ug/mL. Bands of 85kDa and 88kDa are detected
ELISA: use at 5-10ug/mL with prekallikrein sample bound to ELISA plates.
These are recommended concentrations.
Endusers should determine optimal concentrations for their applications.
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Description
Description
SpecificityThis antibody recognizes two variants of prekallikrein in human plasma, 88kDa and
85kDa, and its activation products kallikrein, the complexes formed by kallikrein with its
endogenous inhibitors C1 inhibitor, alpha-2-macroglobulin and antithrombin III, and 45kDa
prekallikrein/kallikrein fragments. It also recognizes prekallikrein and its activation products in
chimpanzee, rhesus, and baboon plasmas. The epitope for this antibody is located on the
prekallikrein/kallikrein hevy chain and is involved in the interaction between prekallikrein and
factor XIIa. This antibody inhibits prekallikrein activation in human and rhesus plasmas by ~60-
80% and 55%, respectively. This antibody does not cross-react with tissue kallikrein.
BackgroundHuman prekallikrein, a serine protease zymogen, is present in plasma as two variants, 88kDa and 85kDa, probably due to different carbohydrate content. Approximately 75% of the total prekallikrein in plasma is noncovalently associated with high molecular weight kininogen (HMWK). HMWK mediates binding of prekallikrein to a negatively-charged surface which is required for its optimal activation to kallikrein by activated factor XII. Although kallikrein light and heavy chains can behave as functionally independent domains, the interaction between these two chains is essential for full biologic activity.
FunctionThe enzyme cleaves Lys-Arg and Arg-Ser bonds. It activates, in a reciprocal reaction, factor XII after its binding to a negatively charged surface. It also releases bradykinin from HMW kininogen and may also play a role in the renin-angiotensin system by converting prorenin into renin.
References & Citations
Das A et al. Biochim Biophys Acta 1571: 225-38 (2002).
Campbell DJ et al. Am J Physiol Integrative Comp Physiol 281: R1059-70 (2001).
Veloso D. Immunopharmacology 33: 374-6 (1996).
Veloso D et al. Thrombosis and Haemostatis 68: 526-533 (1992).
Veloso D and Colman RW. Thrombosis and Haemostatis 65: 382-8°C8 (1991).
Veloso D et al. Adv Exp Med Biol 247: 499-505 (1989).
Veloso D et al. Blood 70: 1053-62 (1987).
Certificate of Analysis